Article
Author(s):
Loucq discusses initial results of a trial of the experimental malaria vaccine RTS,S in which risk of infection was cut in half.
BOSTON, MA—In this interview at the annual conference of the Infectious Diseases Society of America, Christian Loucq, MD, director of the PATH Malaria Vaccine Initiative, discusses promising initial results of a Phase III trial of the experimental malaria vaccine RTS,S.
Real-World Study Confirms Similar Efficacy of Guselkumab and IL-17i for PsA